Kalshi to Offer Prediction Market Bets on Clinical Trials and Regulatory Approvals

Kalshi, one of the world’s largest prediction‑market exchanges, announced it will start allowing bets on the outcomes of clinical trials and regulatory approvals. The initiative could give investors and drug developers a new way to gauge the likelihood of trial success and market entry.

The move reflects growing interest in market‑based signals to assess drug‑development risk, although the platform’s exact mechanics and scope were not detailed in the brief announcement.

The newsletter also highlighted other pharma news, noting Merck’s ongoing work on a cholesterol pill and Lilly’s acquisition of AtaiBeckley, a company developing psychedelic treatments for mental‑health conditions.